Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients: by week 28, 83% achieved complete or partial response, and 67% achieved > 80% reduction in urine protein creatinine ratio Announced the pending acquisition of Metacrine, expected to add $35 million in cash at closing to Equillium’s balance sheet … [Read more…]
